



## NIAID Strategic Plan for Biodefense Research



## NIAID Biodefense Research Agenda for CDC Category A Agents



## NIAID Biodefense Research Agenda for CDC Category A Agents

### Progress Report



August 2003



## NIAID Biodefense Research Agenda for Category B and C Priority Pathogens



## NIAID Biodefense Research Agenda for Category B and C Priority Pathogens

### Progress Report



June 2004



January 2003



05.2005

## NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Radiological and Nuclear Threats



Department of Health and Human Services  
National Institutes of Health  
National Institute of Allergy and Infectious Diseases  
NIH Publication No. 05-5608



# NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats




# Biodefense Countermeasures: Key Achievements

---


## ■ Smallpox

- Dryvax; MVA; antiviral drugs




## ■ Anthrax

- rPA; antitoxins




## ■ Botulinum

- Vaccine; antitoxins



## ■ Ebola

- First human vaccine trials





# **Recent NIH Awards Using BioShield Authorities**

---

## **Awards (\$29M):**

- **Therapeutics for CDC Category A Agents**
- **Development and Production of Antibodies that Protect Against Botulinum Toxin Type A**
- **Production of a Vaccine Candidate Against Botulinum Toxin Type E**


# **Future NIH Awards Using BioShield Authorities**

---

## **Future Awards:**

- **Protecting the Immune System Against Radiation: BioShield Accelerated Product Development (FY 2005; \$4M)**
- **Development of Improved DTPA for Radionuclide Chelation (FY 2005; \$6M)**
- **Assays for Influenza Therapeutics (FY 2006; \$10M)**

# Budgeted Milestones for Development of BioShield Priority Countermeasures



\*\*\* Previously licensed for other indications